TS 155-2
TS 155-2 (JBIR 100), an antimicrobial agent, is a Bafilomycin analogue and an antibiotic. TS 155-2 can be isolated from a culture of Streptomyces sp. TS 155-2 inhibits V-ATPase activity. V-ATPase is correlated with an increasing number of diseases such as osteopetrosis, male infertility and renal acidosis.
For research use only. We do not sell to patients.
- CAS No.: 1314486-37-7
- Formula: C39H60O11
- Molecular Weight:704.89
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-17567A
Heparin sodium saltAnticoagulant -
HY-P1929
BivalirudinThrombin Inhibitor -
HY-10163
DabigatranThrombin Inhibitor -
HY-17567C
Heparin sodium salt (MW 15kDa)Anticoagulant Agent -
HY-10274
Dabigatran etexilateAntithrombotic Agent -
HY-10163R
Dabigatran (Standard)Thrombin Inhibitor -
HY-10274A
Dabigatran etexilate mesylateAntithrombotic Agent -
HY-17378
Dabigatran ethyl esterNQO2 Inhibitor/Thrombin Inhibitor -
HY-10274R
Dabigatran etexilate (Standard)Antithrombotic Agent -
HY-10274AR
Dabigatran etexilate mesylate (Standard)Antithrombotic Agent
All Antibiotic Isoforms
More
Biological Activity
Description
In Vitro
TS 155-2 shows cytotoxic effect against HeLa cells (IC50: 72.6 nM) at 48 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1314486-37-7
-
Molecular Weight 704.89
-
Formula C39H60O11
-
SMILES
O=C(O[C@@H]1C[C@@]([C@@H](C)[C@H](O)[C@@H]([C@H]([C@@H](OC)/C=C/C=C(C)/C[C@H](C)[C@H](O)[C@H](C)/C=C(C)/C=C2\C)OC2=O)C)(O)O[C@H](C(C)C)[C@H]1C)/C=C/C(O)=O
-
Synonyms
JBIR 100
-
Structure Classification
-
Initial Source
Streptomyces sp. IR027-SDHV6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Ueda JY, et al. A new 16-membered tetraene macrolide JBIR-100 from a newly identified Streptomyces species. J Antibiot (Tokyo). 2010 Oct;63(10):627-9. [Content Brief]
[2]. Molloy EM, et al. Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products. Bioorg Med Chem. 2016 Dec 15;24(24):6276-6290. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TS 155-2 Related Classifications
HY-123095 Related Classifications
Powered by Bioz